Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - HOLOGIC INCv467134_ex99-1.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

______________________

 

FORM 8-K

______________________

 

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 15, 2017

______________________

 

HOLOGIC, INC.

(Exact name of registrant as specified in its charter)

______________________

 

         
Delaware     1-36214   04-2902449

(State or other jurisdiction

of incorporation)

 

 

(Commission

File Number)

 

 

(IRS Employer

Identification No.)

 

 

250 Campus Drive, Marlborough, MA   01752
(Address of principal executive offices)   (Zip Code)

 

(508) 263-2900

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

______________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 15, 2017, the Board of Directors of the Hologic, Inc. (the “Company”) elected Charles J. Dockendorff as a director of the Company, effective immediately. Mr. Dockendorff was formerly the executive vice president and chief financial officer of Covidien plc.

 

Mr. Dockendorff, who will stand for election by stockholders at the Company’s 2018 Annual Meeting of Stockholders, has been appointed to serve on the Audit and Finance Committee of the Board of Directors. As a non-employee director of the Company, Mr. Dockendorff will receive compensation as described in the “Director Compensation” section of the Company’s 2017 Proxy Statement.

 

A copy of the Company’s press release announcing the election of Mr. Dockendorff is filed with this Current Report on Form 8-K as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit
Number
  Description
99.1   Press Release dated May 16, 2017.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

Date: May 16, 2017 HOLOGIC, INC.
   
  By:  /s/ John M. Griffin
    John M. Griffin
General Counsel

  

 

 

  

EXHIBIT INDEX

 

Exhibit
Number
  Description
99.1   Press Release dated May 16, 2017.